Faron selects humanisation partner Abzena to make cancer antibody

By Dan Stanton contact

- Last updated on GMT

Image: iStock/Svisio
Image: iStock/Svisio

Related tags: Immune system

Abzena will make Faron's drug candidate Clevegen - an antibody that neutralises a subset of immune cells linked to tumor proliferation - at a recently acquired single-use facility in California.

Clevegen binds a receptor called Clever-1 on the surface of Tumour Associated Macrophages (TAM), which are immune cells that have been linked to tumor profileration and survival.

The idea is that binding Clever-1 prevents TAM cells from entering tumors and exerting any immunosuppressive effects.

Under the manufacturing deal Abzena will produce the Master Cell Bank and make Phase I and II clinical volumes of the antibody at its single-use equipped facility in San Diego, California, acquired last September​ through the purchase of CDMO PacificGMP.

“Faron selected Abzena to optimise and manufacture Clevegen based on Abzena’s high level of expertise and know-how in antibody and protein engineering as well as cell line development and documentation, which can be used both in Europe and USA,”​ Faron’s CEO Markku Jalkanen said.

The terms of the agreement between the two companies are currently not disclosed.

However, Jalkanen told Biopharma-Reporter.com the firm is also working with Selexis which has produced high-expressing and stable clonal cell lines for Clevegen.

“The best selected clone will be now be used by Abzena to produce the Master Cell Bank for Faron. There will be co-operation between all parties.”

Humanisation technology

We asked Abzena if this deal marks the first contract win for Abzena since it added the biopharma cGMP capacity through the PacificGMP acquisition.

“This is not the first manufacturing contract we have been won since Abzena acquired PacificGMP, but it is the first for an ‘Abzena inside’ product since the acquisition,”​ said Dr Sally Waterman, SVP corporate development at Abzena.

Abzena has been helping to develop Clevegen, humanising the antibody using its proprietary Composite Human Antibody technology.

“Abzena’s technology tries to make non-human therapeutic antibodies - e.g. those derived from mice, llamas etc - as human-like as possible, to reduce any unwanted immune responses,”​ Waterman told us.

“Its Composite Human Antibodies are built using multiple sequence segments from unrelated human antibodies as building blocks.”

She added the technology is different to standard humanising techniques because it removes T-cell epitopes which are known to produce immune responses.

Related news

Show more

Related products

show more

Liposomal and Nanoparticle Technology

Liposomal and Nanoparticle Technology

Pfizer CentreOne | 18-Nov-2022 | Technical / White Paper

Medical science is continuously searching for better ways to administer drugs into the body and to maximize the therapeutic effectiveness of the drugs...

Connectivity & Integration in Biomanufacturing

Connectivity & Integration in Biomanufacturing

Wheeler Bio | 17-Nov-2022 | Technical / White Paper

As the Pharma 4.0 initiative sets a new industry paradigm, more biomanufacturing companies are asking how they can design and build facilities that apply...

Scalability, Quality, and Speed with Transposons

Scalability, Quality, and Speed with Transposons

Wheeler Bio | 20-Oct-2022 | Technical / White Paper

To solve for the significant bottlenecks often presented by conventional cell line development processes, this article discusses how Wheeler Bio is leveraging...

Accelerating Time to IND with Pharma 4.0

Accelerating Time to IND with Pharma 4.0

Wheeler Bio | 22-Sep-2022 | Technical / White Paper

The future of the biopharmaceutical industry hinges on its adoption of 21st-century digital tools and automation.

Related suppliers

Follow us

Products

View more

Webinars